Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Background: Hypertrophic cardiomyopathy is a primary cardiac disease characterized by left ventricular hypertrophy, myocyte hypertrophy and irregularities and interstitial fibrosis in the absence of any cardiac or systemic diseases and may lead to sudden cardiac death (SCD). Galectin-3 is a ß-galactoside-binding lectin that has been associated with cardiac fibrosis and inflammation. In this study, we aimed to investigate the relationship between serum galectin-3 levels and the criteria for 5-year sudden death risk, recently defined in the European Society of Cardiology guidelines (2014), in patients with hypertrophic cardiomyopathy. Materials and Methods: A total of 52 hypertrophic cardiomyopathy patients were enrolled in the study. Patients were questioned for sudden death risk predictors as outlined in the 2014 European Society of Cardiology guideline. A standardized clinical evaluation was carried out on the basis of previously described prognostic variables to calculate the 5-year risk of SCD. Blood samples were taken from all patients to measure serum galectin-3 levels. A statistical significance level of P < 0.05 was accepted in all tests. Results: We found that there was a significant correlation between the estimated 5-year risk of SCD and serum levels of galectin-3. Conclusions: Galectin-3 may be an inexpensive and easily accessible parameter to predict arrhythmia risk. In addition, it can be used to determine antiarrhythmic prophylaxis as a predictor of an arrhythmia storm in implantable cardioverter defibrillator-implanted patients who are not available for magnetic resonance imaging. © 2018 Southern Society for Clinical Investigation

Yazar Emet S.
Dadashov M.
Sonsoz M.R.
Cakir M.O.
Yilmaz M.
Elitok A.
Bilge A.K.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/5946
Tek Biçim Adres 10.1016/j.amjms.2018.08.013
Konu Başlıkları Galectin-3
Hypertrophic cardiomyopathy
Risk score
Sudden cardiac death
Ventricular arrhythmias
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı American Journal of the Medical Sciences
Dergi Cilt Bilgisi 356
Dergi Sayısı 6
Sayfalar 537 - 543
Yayın Yılı 2018
Eser Adı
[dc.title]
Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Yazar
[dc.contributor.author]
Emet S.
Yazar
[dc.contributor.author]
Dadashov M.
Yazar
[dc.contributor.author]
Sonsoz M.R.
Yazar
[dc.contributor.author]
Cakir M.O.
Yazar
[dc.contributor.author]
Yilmaz M.
Yazar
[dc.contributor.author]
Elitok A.
Yazar
[dc.contributor.author]
Bilge A.K.
Yayın Yılı
[dc.date.issued]
2018
Yayıncı
[dc.publisher]
Elsevier B.V.
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: Hypertrophic cardiomyopathy is a primary cardiac disease characterized by left ventricular hypertrophy, myocyte hypertrophy and irregularities and interstitial fibrosis in the absence of any cardiac or systemic diseases and may lead to sudden cardiac death (SCD). Galectin-3 is a ß-galactoside-binding lectin that has been associated with cardiac fibrosis and inflammation. In this study, we aimed to investigate the relationship between serum galectin-3 levels and the criteria for 5-year sudden death risk, recently defined in the European Society of Cardiology guidelines (2014), in patients with hypertrophic cardiomyopathy. Materials and Methods: A total of 52 hypertrophic cardiomyopathy patients were enrolled in the study. Patients were questioned for sudden death risk predictors as outlined in the 2014 European Society of Cardiology guideline. A standardized clinical evaluation was carried out on the basis of previously described prognostic variables to calculate the 5-year risk of SCD. Blood samples were taken from all patients to measure serum galectin-3 levels. A statistical significance level of P < 0.05 was accepted in all tests. Results: We found that there was a significant correlation between the estimated 5-year risk of SCD and serum levels of galectin-3. Conclusions: Galectin-3 may be an inexpensive and easily accessible parameter to predict arrhythmia risk. In addition, it can be used to determine antiarrhythmic prophylaxis as a predictor of an arrhythmia storm in implantable cardioverter defibrillator-implanted patients who are not available for magnetic resonance imaging. © 2018 Southern Society for Clinical Investigation
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Galectin-3
Konu Başlıkları
[dc.subject]
Hypertrophic cardiomyopathy
Konu Başlıkları
[dc.subject]
Risk score
Konu Başlıkları
[dc.subject]
Sudden cardiac death
Konu Başlıkları
[dc.subject]
Ventricular arrhythmias
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0002-9629
İlk Sayfa Sayısı
[dc.identifier.startpage]
537
Son Sayfa Sayısı
[dc.identifier.endpage]
543
Dergi Adı
[dc.relation.journal]
American Journal of the Medical Sciences
Dergi Sayısı
[dc.identifier.issue]
6
Dergi Cilt Bilgisi
[dc.identifier.volume]
356
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1016/j.amjms.2018.08.013
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/5946
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
49
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
18 Mayıs 2024 22:19
Google Kontrol
Tıklayınız
cardiac patients sudden galectin-3 Society levels 5-year cardiomyopathy European arrhythmia hypertrophic between Cardiology fibrosis Galectin-3 hypertrophy Results samples measure statistical significance correlation significant accepted estimated Background parameter Conclusions cardioverter Clinical Southern imaging resonance magnetic available
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms